Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Drug Sensitivity and Treatment Response Are Modulated By the Cell of Origin, the Underlying Gene Fusion, and Patient Age in KMT2A -Rearranged BCP-ALL

Blood (2024) 144 (Supplement 1): 318.

https://doi.org/10.1182/blood-2024-199017

Published: 2024

Journal Articles

Data-Informed, Refined Immunophenotypic Classification of Adult T-Lineage Acute Lymphoblastic Leukemia

Stefan Habringer, Iva Todorova, Frederik Herzberg, Daniel Steiert, Arik Horne, Thomas Burmeister, Simon Haas, Ulrich Keller, Monika Brüggemann, Michaela Kotrova, Claudia D Baldus, Nicola Goekbuget, Martin Neumann, Stefan Schwartz

Blood (2024) 144 (Supplement 1): 1460.

https://doi.org/10.1182/blood-2024-202301

Published: 2024

Journal Articles

IDH2 Mutations from Clonal Hematopoiesis and Acquired IKZF1 Deletions Define a Novel B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma

Blood (2024) 144 (Supplement 1): 631.

https://doi.org/10.1182/blood-2024-199601

Published: 2024

Journal Articles

Reshaping MRD Detection Strategies: Next-Generation Sequencing and High DNA Input Identify Previously Missed Measurable Residual Disease in Peripheral Blood of B-Cell Precursor Acute Lmyphoblastic Leukemia

Sonja Bendig, Sandra Bufe, Birgit Fricke, Constantin Proske, Nikos Darzentas, Britta Kehden, Guranda Chitadze, Claudia D Baldus, Michaela Kotrova, Nicola Goekbuget, Monika Brüggemann

Blood (2023) 142 (Supplement 1): 4354.

https://doi.org/10.1182/blood-2023-174458

Published: 2023

Journal Articles

Somatic TP53 mutations are preleukemic events in acute lymphoblastic leukemia

Blood (2023) 141 (13): 1640–1644.

https://doi.org/10.1182/blood.2022017249

Published: 2023

Includes: Supplemental data

Journal Articles

NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol

Michael Svaton, Aneta Skotnicova, Leona Reznickova, Andrea Rennerova, Tatana Valova, Michaela Kotrova, Vincent H. J. van der Velden, Monika Brüggemann, Nikos Darzentas, Anton W. Langerak, Jan Zuna, Jan Stary, Jan Trka, Eva Fronkova

Blood (2023) 141 (5): 529–533.

https://doi.org/10.1182/blood.2022017003

Published: 2023

Includes: Supplemental data

Journal Articles

Disease Kinetics Measured By Circulating Tumor DNA Correlates with Treatment Response after Tafasitamab in Combination with R-CHOP with or without Lenalidomide in First Line Treatment of DLBCL

Mouhamad Khouja, Anke Schilhabel, Michaela Kotrova, Monika Brüggemann, Christian Kuffer, Derek Blair, Nikos Darzentas, Christiane Pott

Blood (2021) 138 (Supplement 1): 3498.

https://doi.org/10.1182/blood-2021-153176

Published: 2021

Journal Articles

NGS-Based MRD Quantitation: An Alternative to qPCR Validated on a Large Consecutive Cohort of Children with ALL

Michael Svaton, Aneta Skotnicova, Leona Reznickova, Andrea Rennerova, Tatana Valova, Michaela Kotrova, Vincent H.J. van der Velden, Monika Brüggemann, Nikos Darzentas, Anton W. Langerak, Jan Zuna, Jan Stary, Jan Trka, Eva Fronkova

Blood (2021) 138 (Supplement 1): 1314.

https://doi.org/10.1182/blood-2021-152971

Published: 2021

Journal Articles

Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1

Blood (2020) 136 (25): 2851–2863.

https://doi.org/10.1182/blood.2020008553

Published: 2020

Includes: Supplemental data

Journal Articles

Monitoring of the Clonal Architecture of B-Cell Precursor ALL during Induction Chemoimmunotherapy

Michaela Kotrova, MD PhD, Monika Szczepanowski, PhD, Henrik Knecht, PhD, Christoph Faul, MD, Mustafa Kondakci, MD, Björn Steffen, MD, Andreas Viardot, MD, Michael Kneba, Dieter Hoelzer, MD PhD, Nicola Goekbuget, MD, Nikos Darzentas, PhD, Monika Brüggemann

Blood (2018) 132 (Supplement 1): 1555.

https://doi.org/10.1182/blood-2018-99-112844

Published: 2018

Journal Articles

The IG/TR Next Generation Marker Screening Developed within Euroclonality-NGS Consortium Is Successful in 94% of Acute Lymphoblastic Leukemia Samples

Michaela Kotrova, MD PhD, Henrik Knecht, PhD, Dietrich Herrmann, Martin Schwarz, Karin Olsen, Heiko Trautmann, PhD, Nicola Goekbuget, MD, Christiane Pott, Nikos Darzentas, PhD, Monika Brüggemann

Blood (2018) 132 (Supplement 1): 2830.

https://doi.org/10.1182/blood-2018-99-112828

Published: 2018

Journal Articles

Immune Reconstitution after Allogeneic Stem Cell Transplantation - a Systematic Single Center Survey

Anna Sophie Hartjen, Andreas Krumbholz, MD, Florian Thieme, PhD, Natalie Schub, MD, Andreas Humpe, MD, Michaela Kotrova, Monika Brüggemann, MD, Martin Gramatzki, MD, Andreas Guenther, MD

Blood (2017) 130 (Supplement 1): 5490.

https://doi.org/10.1182/blood.V130.Suppl_1.5490.5490

Published: 2017

Journal Articles

Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia

Blood (2017) 129 (3): 347–357.

https://doi.org/10.1182/blood-2016-07-726307

Published: 2017

Includes: Supplemental data

Journal Articles

NGS-Based Minimal Residual Disease (MRD) after Stem Cell Transplantation (SCT) Is More Specific for Relapse Prediction Than qPCR and Suggests the Possibility of False-Positive qPCR Results

Michaela Kotrova, MD, Vincent H.J. van der Velden, PhD, Jacques J.M. van Dongen, MD PhD, Renata Formankova, MD PhD, Petr Sedlacek, MD PhD, Monika Brüggemann, MD PhD, Jan Zuna, MD PhD, Jan Stary, MD, Jan Trka, MD PhD, Eva Fronkova, M. D., Ph. D.

Blood (2016) 128 (22): 3494.

https://doi.org/10.1182/blood.V128.22.3494.3494

Published: 2016

Journal Articles

Distinct bilineal leukemia immunophenotypes are not genetically determined

Michaela Kotrova, Alena Musilova, Jan Stuchly, Karel Fiser, Julia Starkova, Ester Mejstrikova, Jan Stary, Jan Zuna, Ondrej Hrusak, Jan Trka, Marketa Zaliova

Blood (2016) 128 (18): 2263–2266.

https://doi.org/10.1182/blood-2016-07-725861

Published: 2016

Includes: Supplemental data

Journal Articles

Library Preparation Is the Major Factor Affecting Differences in Results of Immunoglobulin Gene Rearrangements Detection on Two Major Next-Generation Sequencing Platforms

Blood (2015) 126 (23): 1411.

https://doi.org/10.1182/blood.V126.23.1411.1411

Published: 2015

Journal Articles

The predictive strength of next-generation sequencing MRD detection for relapse compared with current methods in childhood ALL

Michaela Kotrova, Katerina Muzikova, Ester Mejstrikova, Michaela Novakova, Violeta Bakardjieva-Mihaylova, Karel Fiser, Jan Stuchly, Mathieu Giraud, Mikaël Salson, Christiane Pott, Monika Brüggemann, Marc Füllgrabe, Jan Stary, Jan Trka, Eva Fronkova

Blood (2015) 126 (8): 1045–1047.

https://doi.org/10.1182/blood-2015-07-655159

Published: 2015

Includes: Supplemental data

Journal Articles

Next Generation Amplicon Sequencing of Immunoglobulin Heavy Chain Gene Rearrangaments for Minimal Residual Disease (MRD) Stratification in Childhood Acute Lymphoblastic Leukemia (ALL): A Comparison with Classical qPCR-Based Technique

Michaela Kotrova, MD, Katerina Muzikova, M.Sc., Ester Mejstrikova, MD, PhD, Michaela Novakova, Violeta Bakardjieva-Mihaylova, M.Sc., Fiser Karel, PhD, Jan Stuchly, M.Sc., Christiane Pott, M..D, PhD, Monika Bruggemann, MD, PhD, Stary Jan, MD, D.Sc., Prof., Jan Trka, MD, PhD, Prof., Eva Fronkova, MD, PhD

Blood (2014) 124 (21): 2395.

https://doi.org/10.1182/blood.V124.21.2395.2395

Published: 2014

NARROW

Drug Sensitivity and Treatment Response Are Modulated By the Cell of Origin, the Underlying Gene Fusion, and Patient Age in KMT2A -Rearranged BCP-ALL

Data-Informed, Refined Immunophenotypic Classification of Adult T-Lineage Acute Lymphoblastic Leukemia

IDH2 Mutations from Clonal Hematopoiesis and Acquired IKZF1 Deletions Define a Novel B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma

Reshaping MRD Detection Strategies: Next-Generation Sequencing and High DNA Input Identify Previously Missed Measurable Residual Disease in Peripheral Blood of B-Cell Precursor Acute Lmyphoblastic Leukemia

Somatic TP53 mutations are preleukemic events in acute lymphoblastic leukemia

NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol

Disease Kinetics Measured By Circulating Tumor DNA Correlates with Treatment Response after Tafasitamab in Combination with R-CHOP with or without Lenalidomide in First Line Treatment of DLBCL

NGS-Based MRD Quantitation: An Alternative to qPCR Validated on a Large Consecutive Cohort of Children with ALL

Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1

Monitoring of the Clonal Architecture of B-Cell Precursor ALL during Induction Chemoimmunotherapy

The IG/TR Next Generation Marker Screening Developed within Euroclonality-NGS Consortium Is Successful in 94% of Acute Lymphoblastic Leukemia Samples

Immune Reconstitution after Allogeneic Stem Cell Transplantation - a Systematic Single Center Survey

Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia

NGS-Based Minimal Residual Disease (MRD) after Stem Cell Transplantation (SCT) Is More Specific for Relapse Prediction Than qPCR and Suggests the Possibility of False-Positive qPCR Results

Distinct bilineal leukemia immunophenotypes are not genetically determined

Library Preparation Is the Major Factor Affecting Differences in Results of Immunoglobulin Gene Rearrangements Detection on Two Major Next-Generation Sequencing Platforms

The predictive strength of next-generation sequencing MRD detection for relapse compared with current methods in childhood ALL

Next Generation Amplicon Sequencing of Immunoglobulin Heavy Chain Gene Rearrangaments for Minimal Residual Disease (MRD) Stratification in Childhood Acute Lymphoblastic Leukemia (ALL): A Comparison with Classical qPCR-Based Technique

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only